The product called Octaplex, currently under review by the Food and Drug Administration, would reverse the effects of warfarin — an oral drug that reduces blood clotting — in cases of major bleeding.

FRESNO COUNTY, Calif. (KFSN) -- Octapharma Plasma has closed all of its locations nationwide, including in Southeast Fresno and Clovis, citing network issues as the problem. The company pays people to ...

Octapharma Plasma says all of its more than 195 blood-plasma collection centers in 35 states nationwide — including three in Columbus — have been closed by what the company is blaming on IT "network ...

Paramus-based Octapharma USA is supporting a new investigator-initiated clinical trial led by Dr. George Sakoulas of Sharp Memorial Hospital in San Diego, Calif., focused on treating the most critical ...

International Manufacturer of Human Protein Medicines Selects the Leader in Revenue Management for Greater Accuracy and Efficiencies in Provider Intelligence and Management Octapharma’s selection of ...

LACHEN, Switzerland--(BUSINESS WIRE)--Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products. I am ...

HOBOKEN, N.J. (May 13, 2010) - Octapharma USA today announced that wilate®, the first replacement therapy development specifically for von Willebrand Disease (VWD), is now available from the ...

LACHEN, Switzerland--(BUSINESS WIRE)--Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Octapharma delivered an exceptionally strong result in 2019. We achieved ...

PARAMUS, N.J. (December 2, 2020) - Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use ...

FVIII inhibitor development is the most serious treatment complication in previously untreated patients (PUPs) with severe haemophilia A. The development of inhibitors against exogenous FVIII can ...